Ubs Group Ag Kazia Therapeutics LTD Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KZIA
# of Institutions
16Shares Held
1.73MCall Options Held
24KPut Options Held
0-
Mai Capital Management1.36MShares$8.67 Million0.01% of portfolio
-
Morgan Stanley New York, NY201KShares$1.28 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA41.5KShares$263,8000.0% of portfolio
-
Virtu Financial LLC New York, NY39.3KShares$249,8010.0% of portfolio
-
Commonwealth Equity Services, LLC30.5KShares$193,9800.0% of portfolio
About KAZIA THERAPEUTICS LTD
- Ticker KZIA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,111,300
- Market Cap $96.1M
- Description
- Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...